Wednesday |
Options
|
Notable gainers among… Notable gainers among liquid option names this morning include Norwegian Cruise Lines (NCLH) $13.09 +0.99, Caesars (CZR) $49.72 +3.62, Royal Caribbean (RCL) $40.68 +2.71, Carnival (CCL) $10.14 +0.67, and SVB Capital II (SIVB) $444.23 +24.46. ShowHide Related Items >><< - $435.00 /
+15.92 (+3.80%) - 04/19/22
- SVB Financial to rebrand its four primary businesses under SVB
- 07/28/22
- Royal Caribbean actively managing inflationary pressures
- 07/28/22
- Royal Caribbean has returned to typical booking, cancellation policies
- 07/28/22
- Royal Caribbean: Cruise interest 'basically back to 2019 levels'
- 07/28/22
- Royal Caribbean expects to report a net loss in 2H22
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line: Booking trends for FY23 remain 'positive'
- 08/09/22
- Norwegian Cruise Line 'encouraged' by continued strong consumer demand
- 08/09/22
- Norwegian Cruise Line expects to report a net loss for Q3
- 08/08/22
- Norwegian Cruise Line revises vaccination, testing protocols
- 08/02/22
- Caesars expects occupancy in the high 90 percent range from September and beyond
- 08/02/22
- Caesars Sportsbook goes live with online sports betting in Wyoming
- 07/28/22
- Nevada reports June statewide gaming win up 8.06% to $1.28B
- 07/15/22
- New Jersey reports June gaming revenue up 2.2% to $401.5M
- 08/04/22
- Carnival upgrading global fleet with fuel- and energy-saving technology
- 08/01/22
- Carnival welcomes 3M guests since restart of guest operations in July 2021
- 07/21/22
- Carnival falls -11.8%
- 07/21/22
- Carnival falls -13.6%
NCLH Norwegian Cruise Line - 08/10/22 Deutsche Bank
- Norwegian Cruise Line price target lowered to $16 from $17 at Deutsche Bank
- 08/10/22 Susquehanna
- Norwegian Cruise Line price target lowered to $15 from $20 at Susquehanna
- 08/10/22 Credit Suisse
- Norwegian Cruise Line price target lowered to $25 from $33 at Credit Suisse
- 06/29/22 Barclays
- Barclays initiates cruise line space with Royal Caribbean top pick
- 08/03/22 B. Riley
- Caesars shares remain 'woefully undervalued,' says B. Riley
- 08/03/22 Cowen
- Caesars price target lowered to $87 from $105 at Cowen
- 08/03/22 Deutsche Bank
- Caesars price target lowered to $64 from $90 at Deutsche Bank
- 08/03/22 Barclays
- Caesars price target raised to $65 from $56 at Barclays
- 07/29/22 Wells Fargo
- Royal Caribbean price target lowered to $58 from $81 at Wells Fargo
- 07/29/22 Deutsche Bank
- Royal Caribbean price target lowered to $48 from $50 at Deutsche Bank
- 07/29/22 Susquehanna
- Royal Caribbean price target lowered to $50 from $70 at Susquehanna
- 07/22/22 Truist
- Carnival price target lowered to $8 from $15 at Truist
- 07/21/22 Stifel
- Carnival selloff 'coming for sure' as equity raise will cause panic, says Stifel
- 07/04/22 HSBC
- HSBC says too early to call inflection point for Carnival
- 06/29/22 Morgan Stanley
- Morgan Stanley cuts Carnival price target to $7, sees bear case of zero
- $435.00 /
+15.92 (+3.80%) - 08/09/22 JPMorgan
- JPMorgan says 'now is the time to buy' SVB Financial
- 07/25/22 Maxim
- SVB Financial price target lowered to $900 from $1,100 at Maxim
- 07/25/22 Truist
- SVB Financial price target lowered to $500 from $557 at Truist
- 07/25/22 Barclays
- SVB Financial price target lowered to $638 from $789 at Barclays
- $435.00 /
+15.92 (+3.80%) - 07/21/22
- SVB lowered FY22 NII view to Mid-forties growth from low fifties growth
- 07/21/22
- SVB Financial reports Q2 EPS $5.60, consensus $7.66
- 04/21/22
- SVB Financial reports Q1 EPS $7.92, consensus $5.66
- 07/28/22
- Royal Caribbean sees Q3 adjusted EPS 5c-25c, consensus 91c
- 07/28/22
- Royal Caribbean reports Q2 adjusted EPS ($2.08), consensus ($2.20)
- 07/27/22
- Notable companies reporting before tomorrow's open
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line sees Q3 revenue $1.5B-$1.6B, consensus $1.88B
- 08/09/22
- Norwegian Cruise Line reports Q2 adjusted EPS ($1.14), consensus (86c)
- 08/08/22
- Notable companies reporting before tomorrow's open
- 08/02/22
- Caesars reports Q2 cont ops EPS 16, consensus 17c
- 08/02/22
- Notable companies reporting after market close
- 05/03/22
- Caesars reports Q1 same-store adjusted EBITDA $296M vs. $521M last year
- 05/03/22
- Caesars reports Q1 cont ops EPS ($2.11), consensus ($2.21)
- 06/24/22
- Carnival expects a net loss for Q3
- 06/24/22
- Carnival reports Q2 EPS ($1.61), consensus ($1.08)
- 06/23/22
- Notable companies reporting before tomorrow's open
|
Recommendations
|
Deutsche Bank analyst… Deutsche Bank analyst Chris Woronka lowered the firm's price target on Norwegian Cruise Line to $16 from $17 and keeps a Hold rating on the shares. The analyst saw some positive data points in the company's Q2 but says "much heavy lifting" remains for 2023. ShowHide Related Items >><< NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line: Booking trends for FY23 remain 'positive'
- 08/09/22
- Norwegian Cruise Line 'encouraged' by continued strong consumer demand
- 08/09/22
- Norwegian Cruise Line expects to report a net loss for Q3
- 08/08/22
- Norwegian Cruise Line revises vaccination, testing protocols
NCLH Norwegian Cruise Line - 08/10/22 Susquehanna
- Norwegian Cruise Line price target lowered to $15 from $20 at Susquehanna
- 08/10/22 Credit Suisse
- Norwegian Cruise Line price target lowered to $25 from $33 at Credit Suisse
- 06/29/22 Barclays
- Barclays initiates cruise line space with Royal Caribbean top pick
- 06/28/22 Barclays
- Norwegian Cruise Line initiated with an Equal Weight at Barclays
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line sees Q3 revenue $1.5B-$1.6B, consensus $1.88B
- 08/09/22
- Norwegian Cruise Line reports Q2 adjusted EPS ($1.14), consensus (86c)
- 08/08/22
- Notable companies reporting before tomorrow's open
NCLH Norwegian Cruise Line - 07/02/22
- Not the time to bottom-fish cruise operator stocks, Barron's says
- 05/02/22
- Fincantieri, Norwegian in discussions over $4B cruise ship order, Reuters says
- 03/02/22
- Carnival, Norwegian update mask policy, now optional for most, WSJ reports
NCLH Norwegian Cruise Line - 08/09/22
- What You Missed On Wall Street On Tuesday
- 08/09/22
- What You Missed On Wall Street This Morning
- 08/09/22
- Fly Intel: Pre-market Movers
- 04/13/22
- What You Missed On Wall Street On Wednesday
NCLH Norwegian Cruise Line - 08/09/22
- Unusually active option classes on open August 9th
- 07/18/22
- Early notable gainers among liquid option names on July 18th
- 07/07/22
- Unusually active option classes on open July 7th
- 06/30/22
- Unusually active option classes on open June 30th
|
Recommendations
|
Susquehanna analyst… Susquehanna analyst Christopher Stathoulopoulos lowered the firm's price target on Norwegian Cruise Line to $15 from $20 and keeps a Positive rating on the shares. The analyst said its elevated exposure to European itineraries in 3Q and labor tightness in higher-yielding Pride of America are clear challenges on the horizon, though obstacles the company should be able to navigate into year end 2022. ShowHide Related Items >><< NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line: Booking trends for FY23 remain 'positive'
- 08/09/22
- Norwegian Cruise Line 'encouraged' by continued strong consumer demand
- 08/09/22
- Norwegian Cruise Line expects to report a net loss for Q3
- 08/08/22
- Norwegian Cruise Line revises vaccination, testing protocols
NCLH Norwegian Cruise Line - 08/10/22 Credit Suisse
- Norwegian Cruise Line price target lowered to $25 from $33 at Credit Suisse
- 06/29/22 Barclays
- Barclays initiates cruise line space with Royal Caribbean top pick
- 06/28/22 Barclays
- Norwegian Cruise Line initiated with an Equal Weight at Barclays
- 06/21/22 Deutsche Bank
- Norwegian Cruise Line price target lowered to $17 from $23 at Deutsche Bank
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line sees Q3 revenue $1.5B-$1.6B, consensus $1.88B
- 08/09/22
- Norwegian Cruise Line reports Q2 adjusted EPS ($1.14), consensus (86c)
- 08/08/22
- Notable companies reporting before tomorrow's open
NCLH Norwegian Cruise Line - 07/02/22
- Not the time to bottom-fish cruise operator stocks, Barron's says
- 05/02/22
- Fincantieri, Norwegian in discussions over $4B cruise ship order, Reuters says
- 03/02/22
- Carnival, Norwegian update mask policy, now optional for most, WSJ reports
NCLH Norwegian Cruise Line - 08/09/22
- What You Missed On Wall Street On Tuesday
- 08/09/22
- What You Missed On Wall Street This Morning
- 08/09/22
- Fly Intel: Pre-market Movers
- 04/13/22
- What You Missed On Wall Street On Wednesday
NCLH Norwegian Cruise Line - 08/09/22
- Unusually active option classes on open August 9th
- 07/18/22
- Early notable gainers among liquid option names on July 18th
- 07/07/22
- Unusually active option classes on open July 7th
- 06/30/22
- Unusually active option classes on open June 30th
|
Recommendations
|
Credit Suisse analyst… Credit Suisse analyst Benjamin Chaiken lowered the firm's price target on Norwegian Cruise Line to $25 from $33 and keeps an Outperform rating on the shares following quarterly results. The analyst notes the company reported total APCD of 4.64M compared to his 4.68M, and occupancy of 64.6% slightly below his estimate. Chaiken thinks the stock underperformance was driven by higher-than-expected cost commentary, partially fueling fears that Norwegian will likely run into a liquidity headwind. The cost comments did "surprise" him, and as a result he takes his earnings estimates down, but still thinks the liquidity math works, in part because of the strong booked position for 2023 even assuming trends decelerate from here. ShowHide Related Items >><< NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line: Booking trends for FY23 remain 'positive'
- 08/09/22
- Norwegian Cruise Line 'encouraged' by continued strong consumer demand
- 08/09/22
- Norwegian Cruise Line expects to report a net loss for Q3
- 08/08/22
- Norwegian Cruise Line revises vaccination, testing protocols
NCLH Norwegian Cruise Line - 06/29/22 Barclays
- Barclays initiates cruise line space with Royal Caribbean top pick
- 06/28/22 Barclays
- Norwegian Cruise Line initiated with an Equal Weight at Barclays
- 06/21/22 Deutsche Bank
- Norwegian Cruise Line price target lowered to $17 from $23 at Deutsche Bank
- 06/09/22 Susquehanna
- Norwegian Cruise Line initiated with a Positive at Susquehanna
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line sees Q3 revenue $1.5B-$1.6B, consensus $1.88B
- 08/09/22
- Norwegian Cruise Line reports Q2 adjusted EPS ($1.14), consensus (86c)
- 08/08/22
- Notable companies reporting before tomorrow's open
NCLH Norwegian Cruise Line - 07/02/22
- Not the time to bottom-fish cruise operator stocks, Barron's says
- 05/02/22
- Fincantieri, Norwegian in discussions over $4B cruise ship order, Reuters says
- 03/02/22
- Carnival, Norwegian update mask policy, now optional for most, WSJ reports
NCLH Norwegian Cruise Line - 08/09/22
- What You Missed On Wall Street On Tuesday
- 08/09/22
- What You Missed On Wall Street This Morning
- 08/09/22
- Fly Intel: Pre-market Movers
- 04/13/22
- What You Missed On Wall Street On Wednesday
NCLH Norwegian Cruise Line - 08/09/22
- Unusually active option classes on open August 9th
- 07/18/22
- Early notable gainers among liquid option names on July 18th
- 07/07/22
- Unusually active option classes on open July 7th
- 06/30/22
- Unusually active option classes on open June 30th
|
Tuesday |
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 07/29/22
- Walmart announces launch of 'Walmart Restored' refurbished sales program
- 07/28/22
- Walmart to open new general stores at Getaway outposts
- 07/26/22
- Walmart partner with WALDO to offer affordable contact lenses
- 07/25/22
- Walmart down 6% after lowering profit outlook for Q2, FY23
- 08/09/22
- Vertex Energy sees 2022 capex $115M-$120M
- 08/09/22
- Vertex Energy sees Q3 total throughput 72,000-74,000 barrels per day at Mobile
- 06/14/22
- Vertex Energy names James Rhame as COO, succeeding John Strickland
- 06/14/22
- Vertex Energy appoints Alvaro Ruiz as chief strategy officer
- 08/09/22
- Verona Pharma surges after ensifentrine meets endpoint in COPD study
- 08/08/22
- Verona Pharma to announce top-line data from Phase 3 trial of Ensifentrine
- 06/09/22
- Verona Pharma completes enrollment in Phase 3 ENHANCE-1 trial
- 05/09/22
- Verona Pharma to present successful TQT analysis of ensifentrine
- 08/08/22
- Upstart Holdings trading resumes
- 08/08/22
- Upstart Holdings trading halted, news pending
- 06/08/22
- CFPB issues order to terminate Upstart 'no-action letter'
- 05/16/22
- Third Point lowers stakes in Amazon, Intuit, exits Alphabet position
- $850.00 /
-21.19 (-2.43%) - 08/07/22
- Elon Musk challenges Twitter CEO to 'a public debate' on bots
- 08/07/22
- Musk says Twitter deal should not proceed if SEC filings 'materially false'
- 08/05/22
- Tesla confirms three-for-one stock split
- 08/03/22
- American Battery Metals appoints Belanger as Staff Analytical Chemist
- 07/21/22
- Tandem Diabetes acquires Capillary Biomedical, terms not disclosed
- 02/16/22
- Tandem Diabetes announces FDA clearance for t:slim X2 insulin pump
- 08/02/22
- Sysco donates $1M to Feeding America
- 07/13/22
- Sysco appoints Peereboom as EVP, president, foodservice operations
- 05/19/22
- Sysco intends to purchase up to 800 Freightliner eCascadia Class 8 tractors
- 05/14/22
- Trian exits Comcast position, increases stake in Invesco
- 08/09/22
- Ralph Lauren expects further pressure on gross margins near term
- 08/09/22
- Ralph Lauren seeing broad based strength across all regions
- 06/24/22
- Ralph Lauren announces nomination of Cupp to board of directors
- 06/24/22
- Ralph Lauren publishes 2022 Global Citizenship & Sustainability Report
- 08/08/22
- Quanterix executive chairman Krusovsky resigns
- 04/22/22
- Quanterix granted Breakthrough Device designation by the FDA for Simoa
- 03/01/22
- Quanterix, Eli Lilly enter Alzheimer's disease diagnosis collaboration
- 03/01/22
- Quanterix CEO Kevin Hrusovsky to become chairman, Masoud Toloue to succeed
- 07/25/22
- Tim China announces collaboration with Easy Joy
- 07/25/22
- Kitchen United announces $100M Series C fundraise
- 05/16/22
- Pershing Square boosts Canadian Pacific, cuts Domino's in Q1
- 05/05/22
- Regis names Matthew Doctor as CEO
- 08/08/22
- Palantir falls -12.0%
- 08/08/22
- Palantir falls -14.4%
- 08/08/22
- Palantir falls -12.2%
- 07/28/22
- Palantir announces $99.9M contract with U.S. Army Research Laboratory
- 07/25/22
- NFL launches exclusive streaming subscription service NFL+
- 06/21/22
- Paramount+ intends to commission 150 international originals by 2025
- 06/13/22
- AMC says past weekend admissions revenues 15% higher than same period in 2019
- 08/04/22
- Paramount says seeing weakness in macro advertising market
- 08/04/22
- Paramount says direct to consumer losses will be greatest in 2023
- 08/04/22
- Paramount says 'clearly navigating some near term headwinds'
- 08/03/22
- Paramount+ to launch as a Premium Subscription within Roku Channel
- 08/02/22
- Owl Rock announces investment in Amergin Asset Management
- 06/21/22
- Franchise Group announces sale of W.S. Badcock corporation distribution centers
- 04/13/22
- Arko Corp.'s GPM secures $1.15B real property commitment from Oak Street
- 02/16/22
- Blue Owl Capital to acquire Wellfleet Credit Partners from Littlejohn & Co.
- $40.26 /
-17.07 (-29.77%) - 08/08/22
- Novavax drops 30% to $39.59 after cutting FY22 revenue outlook
- 08/08/22
- Novavax trading resumes
- 08/08/22
- Novavax trading halted, news pending
- 08/04/22
- Novavax initiates Phase 2b&3 trial of COVID-19 vaccine in younger children
- 07/27/22
- CarGurus appoints Javier Zamora as general counsel
- 07/19/22
- Skechers down 4% as short-seller Spruce Point sees 30%-50% downside risk
- 06/27/22
- Nike says taking 'cautious approach' to greater China in FY23
- 06/27/22
- Nike says digital now represents 24% of brand revenue
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line: Booking trends for FY23 remain 'positive'
- 08/09/22
- Norwegian Cruise Line 'encouraged' by continued strong consumer demand
- 08/09/22
- Norwegian Cruise Line expects to report a net loss for Q3
- 08/08/22
- Norwegian Cruise Line revises vaccination, testing protocols
- 08/09/22
- Micron to invest $40B to build memory manufacturing in phases in the U.S.
- 07/29/22
- Micron intends to bring memory manufacturing to the U.S.
- 07/26/22
- Micron ships 232-layer NAND
- 07/21/22
- Western Digital, Micron trade lower after Seagate earnings miss
- 08/09/22
- Barclays deploys Microsoft teams as collaboration platform
- 08/08/22
- Take-Two delays 'Marvel's Midnight Suns' to fiscal 2023
- 08/04/22
- Atlassian names Microsoft's Joe Binz as new CFO
- 08/04/22
- Microsoft tests Game Pass family plan in Colombia, Ireland
MRSN Mersana Therapeutics - 08/08/22
- Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056
- 08/08/22
- Mersana Therapeutics trading resumes
- 08/08/22
- Mersana Therapeutics trading halted, news pending
- 05/23/22
- Mersana Therapeutics director Hack buys 216K shares of stock
- 08/09/22
- ironSource falls -14.8%
- 07/20/22
- ironSource rises 14.9%
- 07/13/22
- ironSource rises 42.8%
- 08/08/22
- GSK, IQVIA launch Vaccine Track platform
- 07/29/22
- ViiV Healthcare presents five-year data at AIDS 2022 on fostemsavir
- 07/28/22
- ViiV Healthcare announces data from unblinded phase of HPTN 084 study
- 08/08/22
- GlobalFoundries, Qualcomm extend semiconductor manufacturing agreement
- 07/11/22
- STMicroelectronics, GlobalFoundries to create chip manufacturing facility
- 05/19/22
- GlobalFoundries, Motorola announce strategic agreement for chip supply
- 05/03/22
- GlobalFoundries awarded $117M DoD chip supply deal
- 08/09/22
- GoodRx rallies after saying grocer issue recently addressed
- 05/17/22
- GoodRx announces strategic relationship with RxVantage
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 07/21/22
- FOX Nation expands distribution to FuboTV
- 06/06/22
- Fox Corp. names Gabrielle Brown as chief investor relations officer
- 05/10/22
- Fox Corp. reports Q3 affiliate revenues increased 5%
- 08/03/22
- Fox Corp., Verizon announce new multi-year distribution agreement
- 07/27/22
- Verizon announces six months of Disney+ with Prepaid Unlimited plans
- 07/20/22
- 'Minecraft' developer says NFTs, blockchain tech not allowed in the game
- 07/17/22
- Fly Intel: Top five weekend stock stories
- 07/04/22
- Fly Intel: Top five weekend stock stories
- 06/30/22
- Comcast's Xfinity Stream app launches on Apple TV 4K, Apple TV HD
- 08/01/22
- Comcast Business, Fortinet partner for SASE, SSE solutions
- 07/26/22
- Vizio up 3% after Protocol report on Comcast acquisition talks
- 07/24/22
- Fly Intel: Top five weekend stock stories
- 08/01/22
- Bausch Health credit cut at S&P on 'much more challenging' prospects
- 07/28/22
- Bausch Health trading resumes
- 07/28/22
- Bausch Health to appeal expected court decision on certain Xifaxan patents
- 07/28/22
- Bausch Health 'disappointed' with oral order on Xifaxan patents, plans to appeal
- 08/03/22
- Bed Bath & Beyond down 3% to $5.62 after Bloomberg report on credit talks
- 07/21/22
- Freeman Capital discloses 6.21% stake in Bed Bath & Beyond
- 07/07/22
- Bed Bath & Beyond interim CEO Sue Gove buys 50,000 shares of common stock
ATRA Atara Biotherapeutics - 07/12/22
- Atara Biotherapeutics not to expand sample size in ATA188 Ph2 study
- 06/05/22
- Atara announces clinical data from ongoing tab-cel European Multicenter EAP
- 05/19/22
- Atara Biotherapeutics down 14% at $4.44 after announcing end of Bayer deal
- 05/19/22
- Atara provides update on Bayer collaboration
- 08/09/22
- ironSource drops 10% as AppLovin's Unity bid contingent on ironSource deal exit
- 08/09/22
- AppLovin submits proposal to combine with Unity
- 08/09/22
- AppLovin says proposal to combine would value Unity at $58.85 per share
- 08/09/22
- AppLovin announces non-binding proposal to combine with Unity Software
- $850.00 /
-21.19 (-2.43%) - 08/08/22 Canaccord
- Tesla price target raised to $881 from $815 at Canaccord
- 08/05/22 Susquehanna
- Susquehanna downgrades Twitter on 'uncertainty and disruption' from takeover
- 08/03/22 Morgan Stanley
- Tesla exposed to both risk and opportunity of battery race, says Morgan Stanley
- 08/02/22 Citi
- Tesla price target raised to $424 from $375 at Citi
- 08/08/22 B. Riley
- B. Riley thinks Globalstar's mystery satellite capacity customer is Apple
- 08/04/22 MKM Partners
- 8x8 initiated with a Neutral at MKM Partners
- 08/04/22 Deutsche Bank
- Activision Blizzard price target lowered to $84 from $95 at Deutsche Bank
- 08/03/22 Craig-Hallum
- RingCentral price target lowered to $110 from $175 at Craig-Hallum
- 08/05/22 Deutsche Bank
- Paramount price target lowered to $32 from $35 at Deutsche Bank
- 08/05/22 JPMorgan
- JPMorgan downgrades Paramount to Underweight on soft DTC revenue
- 08/05/22 Morgan Stanley
- Paramount price target lowered to $20 from $22 at Morgan Stanley
- 08/05/22 JPMorgan
- Paramount downgraded to Underweight from Neutral at JPMorgan
- 07/27/22 Evercore ISI
- Fox Corp. price target lowered to $38 from $44 at Evercore ISI
- 07/26/22 Goldman Sachs
- Fox Corp. price target lowered to $30 from $32 at Goldman Sachs
- 07/18/22 Morgan Stanley
- Fox Corp. downgraded to Equal Weight from Overweight at Morgan Stanley
- 05/25/22 Deutsche Bank
- Fox Corp. price target lowered to $46 from $48 at Deutsche Bank
- 06/02/22 Wolfe Research
- Fox Corp. assumed at Peer Perform from Outperform at Wolfe Research
- 04/19/22 Rosenblatt
- Fox Corp. initiated with a Neutral at Rosenblatt
- 12/14/21 Macquarie
- Fox Corp. price target lowered to $37 from $40 at Macquarie
- 08/10/22 Oppenheimer
- Trade Desk price target raised to $78 from $60 at Oppenheimer
- 07/27/22 Evercore ISI
- Disney price target lowered to $130 from $150 at Evercore ISI
- 07/26/22 Truist
- Disney price target lowered to $125 from $135 at Truist
- 07/29/22 BofA
- Amazon price target bumped to $170 at BofA after 'mostly positive' quarter
- 07/28/22 DA Davidson
- Best Buy price target lowered to $88 from $110 at DA Davidson
- 07/28/22 Wells Fargo
- Best Buy price target lowered to $70 from $82 at Wells Fargo
- 07/27/22 Deutsche Bank
- Walmart price target lowered to $142 from $166 at Deutsche Bank
- 08/05/22 Redburn
- Comcast downgraded to Neutral from Buy at Redburn
- 08/01/22 Barclays
- Comcast downgraded to Equal Weight from Overweight at Barclays
- 07/29/22 Cowen
- Comcast price target lowered to $51 from $60 at Cowen
- 07/29/22 Morgan Stanley
- Comcast price target lowered to $50 from $55 at Morgan Stanley
- 07/20/22 KeyBanc
- Disney price target lowered to $131 from $151 at KeyBanc
- 05/23/22 Raymond James
- Electronic Arts moves 'somewhat unexpected,' says Raymond James
- 04/14/22 Oppenheimer
- Comcast price target lowered to $60 from $75 at Oppenheimer
- 03/23/22 Craig-Hallum
- ComScore poised for share gains in local measurement, says Craig-Hallum
- 08/10/22 Benchmark
- Benchmark keeps Sell rating on Unity, doesn't think AppLovin acquires
- 08/10/22 Barclays
- Unity price target raised to $49 from $35 at Barclays
- 08/10/22 Piper Sandler
- Unity price target raised to $42 from $34 at Piper Sandler
- 08/09/22 Stifel
- Unity price target raised to $60 at Stifel after AppLovin proposal
- 08/10/22 Oppenheimer
- Unity price target raised to $60 from $54 at Oppenheimer
- 08/10/22 Citi
- Micron price target lowered to $75 from $80 at Citi
- 08/09/22 Piper Sandler
- Micron weakness in PCs, phones spilling to other markets, says Piper Sandler
- 08/09/22 Raymond James
- Micron downgraded to Outperform at Raymond James on near-term headwinds
- 08/09/22 Raymond James
- Micron downgraded to Outperform from Strong Buy at Raymond James
- 08/10/22 Citi
- GlobalFoundries price target lowered to $67 from $70 at Citi
- 07/27/22 Baird
- CHIPS Act could have deflationary impact on semiconductors, says Baird
- 07/20/22 Deutsche Bank
- GlobalFoundries price target lowered to $55 from $70 at Deutsche Bank
- 07/11/22 Susquehanna
- GlobalFoundries price target lowered to $75 from $85 at Susquehanna
- $40.26 /
-17.07 (-29.77%) - 08/09/22 Cowen
- Novavax price target lowered to $110 from $150 at Cowen
- 07/22/22 B. Riley
- Novavax price target lowered to $171 from $181 at B. Riley
- 06/08/22 B. Riley
- B. Riley sees front line status for Novavax vaccine as mRNA alternative
- 06/08/22 Cowen
- Novavax positive advisory vote removes major overhang, says Cowen
- 08/05/22 Credit Suisse
- Ralph Lauren price target lowered to $120 from $130 at Credit Suisse
- 08/01/22 Deutsche Bank
- Ralph Lauren price target lowered to $99 from $101 at Deutsche Bank
- 07/21/22 Goldman Sachs
- Ralph Lauren price target lowered to $78 from $85 at Goldman Sachs
- 07/15/22 UBS
- Ralph Lauren price target lowered to $129 from $162 at UBS
- 08/09/22 Morgan Stanley
- Palantir price target lowered to $11 from $13 at Morgan Stanley
- 08/09/22 Citi
- Palantir price target lowered to $6 from $7 at Citi
- 08/09/22 Deutsche Bank
- Palantir downgraded to Sell from Hold at Deutsche Bank
- 08/08/22 Jefferies
- Palantir price target lowered to $12 from $13 at Jefferies
- 08/09/22 Baird
- Baird downgrades Bed Bath & Beyond to sell after 86% two-day rally
- 08/09/22 Baird
- Bed Bath & Beyond downgraded to Underperform from Neutral at Baird
- 08/08/22 Odeon Capital
- Bed Bath & Beyond cut to Hold at Odeon Capital following doubling in a week
- 08/08/22 Odeon Capital
- Bed Bath & Beyond downgraded to Hold from Buy at Odeon Capital
- 08/09/22 Exane BNP Paribas
- Nike downgraded to Neutral at Exane BNP Paribas on concerns about FY25 targets
- 08/09/22 Exane BNP Paribas
- Nike downgraded to Neutral from Outperform at Exane BNP Paribas
- 07/25/22 Piper Sandler
- Nike assumed with a Neutral at Piper Sandler
- 07/21/22 KeyBanc
- KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view
- 08/09/22 Argus
- Restaurant Brands upgraded to Buy at Argus on earnings upside
- 08/09/22 Argus
- Restaurant Brands upgraded to Buy from Hold at Argus
- 08/05/22 Baird
- Restaurant Brands price target raised to $63 from $56 at Baird
- 08/05/22 Deutsche Bank
- Restaurant Brands price target raised to $70 from $64 at Deutsche Bank
- 08/09/22 Wells Fargo
- Tandem Diabetes downgraded to Underweight from Overweight at Wells Fargo
- 08/04/22 Craig-Hallum
- Tandem Diabetes price target lowered to $105 from $156 at Craig-Hallum
- 08/04/22 Lake Street
- Tandem Diabetes price target lowered to $150 from $200 at Lake Street
- 08/04/22 Cowen
- Tandem Diabetes price target lowered to $107 from $141 at Cowen
- 08/09/22 Canaccord
- Verona Pharma price target raised to $27 from $24 at Canaccord
- 08/09/22 Wedbush
- Verona Pharma price target raised to $23 from $18 at Wedbush
- 06/17/22 Wedbush
- Verona Pharma price target lowered to $18 from $25 at Wedbush
- 09/13/21
- Fly Intel: Top five analyst initiations
MRSN Mersana Therapeutics - 08/09/22 Baird
- Mersana Therapeutics price target raised to $20 from $18 at Baird
- 05/10/22 Baird
- Mersana Therapeutics price target lowered to $18 from $23 at Baird
- 05/09/22 H.C. Wainwright
- Mersana price target lowered to $19 from $24 at H.C. Wainwright
- 11/10/21 Baird
- Mersana Therapeutics price target lowered to $23 from $30 at Baird
- 08/08/22 UBS
- GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
- 08/05/22 Morgan Stanley
- GSK plc resumed with an Equal Weight at Morgan Stanley
- 07/21/22 Citi
- GSK plc resumed with a Neutral at Citi
ATRA Atara Biotherapeutics - 07/20/22 Citi
- Atara Biotherapeutics downgraded to Sell from Neutral at Citi
- 07/13/22 Canaccord
- Atara Biotherapeutics price target lowered to $50 from $67 at Canaccord
- 07/13/22 Stifel
- Stifel downgrades Atara Biotherapeutics to Hold following ATA188 analysis
- 07/13/22 Stifel
- Atara Biotherapeutics downgraded to Hold from Buy at Stifel
- 08/09/22 Cowen
- Quanterix downgraded to Market Perform from Outperform at Cowen
- 08/09/22 SVB Securities
- Quanterix downgraded to Market Perform from Outperform at SVB Securities
- 05/11/22 Cowen
- Quanterix price target lowered to $38 from $60 at Cowen
- 03/15/22 BTIG
- Quanterix price target lowered to $60 from $92 at BTIG
- 08/10/22 Oppenheimer
- Vertex Energy downgraded to Perform from Outperform at Oppenheimer
- 08/10/22 H.C. Wainwright
- Vertex Energy price target lowered to $15 from $25 at H.C. Wainwright
- 07/07/22 Oppenheimer
- Vertex Energy initiated with an Outperform at Oppenheimer
- 06/08/22 Stifel
- Vertex Energy price target raised to $20 from $14 at Stifel
- 07/29/22 RBC Capital
- Bausch Health downgraded to Sector Perform from Outperform at RBC Capital
- 07/29/22 RBC Capital
- Bausch Health downgraded to Sector Perform from Outperform at RBC Capital
- 07/28/22 Truist
- Bausch Health downgraded to Hold from Buy at Truist
- 07/28/22 Stifel
- Stifel puts Bausch rating under review amid 'significant confusion'
NCLH Norwegian Cruise Line - 08/10/22 Credit Suisse
- Norwegian Cruise Line price target lowered to $25 from $33 at Credit Suisse
- 06/29/22 Barclays
- Barclays initiates cruise line space with Royal Caribbean top pick
- 06/28/22 Barclays
- Norwegian Cruise Line initiated with an Equal Weight at Barclays
- 06/21/22 Deutsche Bank
- Norwegian Cruise Line price target lowered to $17 from $23 at Deutsche Bank
- 08/09/22 Morgan Stanley
- Upstart origination volume may have peaked, says Morgan Stanley
- 08/09/22 Stephens
- Upstart price target lowered to $23 from $28 at Stephens
- 07/22/22 Morgan Stanley
- Berkshire Hills halting additions of new Upstart loans, says Morgan Stanley
- 07/18/22 Piper Sandler
- Upstart price target lowered to $25 from $44 at Piper Sandler
- 08/09/22 Goldman Sachs
- Goldman Sachs raises GoodRx price target to $10 amid grocer issue resolution
- 08/09/22 RBC Capital
- GoodRx price target raised to $11 from $6.50 at RBC Capital
- 08/09/22 Barclays
- GoodRx price target raised to $13 from $12 at Barclays
- 07/20/22 Barclays
- GoodRx price target lowered to $12 from $15 at Barclays
- 08/10/22 Credit Suisse
- Sysco price target lowered to $100 from $107 at Credit Suisse
- 06/29/22 Barclays
- Sysco price target raised to $102 from $97 at Barclays
- 06/09/22 Barclays
- Sysco price target lowered to $97 from $102 at Barclays
- 05/26/22 JPMorgan
- Sysco upgraded to Overweight after recent pullback at JPMorgan
- 08/03/22 Stifel
- AppLovin price target lowered to $50 from $80 at Stifel
- 07/22/22 KeyBanc
- ironSource downgraded to Sector Weight from Overweight at KeyBanc
- 07/11/22 JPMorgan
- Blue Owl Capital initiated with a Neutral at JPMorgan (Thursday)
- 06/08/22 JMP Securities
- Blue Owl Capital initiated with an Outperform at JMP Securities
- 01/24/22 BofA
- Blue Owl Capital initiated with a Buy at BofA
- 01/24/22 BofA
- Blue Owl Capital initiated with a Buy at BofA
- 07/25/22
- Walmart lowers profit outlook for FY23, sees adjusted EPS to decline 10%-12%
- 07/25/22
- Walmart lowers profit outlook for Q2, sees adjusted EPS to decline 8%-9%
- 07/25/22
- Walmart lowers profit outlook for Q2 and FY23
- 05/17/22
- Walmart cuts FY23 EPS view to flat from up 5%-6%, consensus $6.76
- 08/09/22
- Vertex Energy reports Q2 EPS (98c) vs. (38c) last year
- 05/10/22
- Vertex Energy sees FY23 adjusted EBITDA $425M-$450M
- 05/10/22
- Vertex Energy sees FY22 adjusted EBITDA $340M-$360M
- 05/10/22
- Vertex Energy reports Q1 EPS (8c), consensus (14c)
- 08/09/22
- Verona Pharma reports Q2 EPS (4c), consensus (38c)
- 08/08/22
- Upstart sees Q3 revenue $170M, consensus $248.92M
- 08/08/22
- Upstart reports Q2 adjusted EPS 1c, consensus 10c
- 08/08/22
- Notable companies reporting after market close
- 07/07/22
- Upstart cuts Q2 revenue view to $228M from $295M-$305M, consensus $297.68M
- 08/09/22
- Unity sees FY22 revenue $1.3B-$1.35B, consensus $1.36B
- 08/09/22
- Unity sees Q3 revenue $315M-$335M, consensus $346.87M
- 08/09/22
- Unity reports Q2 EPS (18c), consensus (21c)
- 08/09/22
- Notable companies reporting after market close
- $850.00 /
-21.19 (-2.43%) - 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 04/20/22
- Tesla reports Q1 EPS $3.22, consensus $2.26
- 04/20/22
- Notable companies reporting after market close
- 08/03/22
- Tandem Diabetes cuts FY22 revenue view to $835M-$845 from $850M-$865M
- 08/03/22
- Tandem Diabetes reports Q2 EPS (24c), consensus 2c
- 05/04/22
- Tandem Diabetes raises FY22 revenue view to $850M-$865M, consensus $846.54M
- 05/04/22
- Tandem Diabetes reports Q1 EPS (23c), consensus (7c)
- 08/09/22
- Sysco reaffirms FY24 adjusted EPS guidance 30% higher than FY19
- 08/09/22
- Sysco prepared to generate sales growth of at least 10% in 2023
- 08/09/22
- Sysco sees FY23 adjusted EPS $4.09 - $4.39
- 08/09/22
- Sysco reports Q4 adjusted EPS $1.15 vs 71c last year
- 08/09/22
- Ralph Lauren backs FY23 revenue view up high single digits, consensus $6.38B
- 08/09/22
- Ralph Lauren sees Q2 revenue up 11%, consensus $1.58B
- 08/09/22
- Ralph Lauren reports Q1 adjusted EPS $1.88 vs. $2.29 last year
- 08/08/22
- Quanterix reports Q2 revenue $23.5M, consensus $30.1M
- 05/10/22
- Quanterix reports Q1 net loss $18.2M vs.$10.1M loss last year
- 03/01/22
- Quanterix reports Q4 revenue $30.29M, consensus $28.49M
- 08/04/22
- Restaurant Brands reports Q2 EPS 76c, consensus 73c
- 05/03/22
- Restaurant Brands reports Q1 adjusted EPS 64c, consensus 62c
- 02/15/22
- Restaurant Brands reports Q4 EPS 74c, consensus 69c
- 02/14/22
- Notable companies reporting before tomorrow's open
- 08/08/22
- Palantir sees FY22 revenue $1.9B - $1.902B , consensus $1.96B
- 08/08/22
- Palantir sees Q3 revenue $474M - $475M , consensus $506.88M
- 08/08/22
- Palantir reports Q2 EPS (9c) vs. (7c) last year
- 05/09/22
- Palantir sees Q2 revenue base case $470M, consensus $483.84M
- 08/04/22
- Paramount reports Q2 EPS 53c, consensus 62c
- 08/03/22
- Notable companies reporting before tomorrow's open
- 05/03/22
- Paramount reports Q1 EPS 60c, consensus 51c
- 08/04/22
- Blue Owl Capital reports Q2 EPS 0c vs. ($1.23) a year ago
- 02/17/22
- Blue Owl Capital reports Q4 adjusted EPS 12c, consensus 11c
- $40.26 /
-17.07 (-29.77%) - 08/08/22
- Novavax cuts FY22 revenue view to $2B-$2.3B from $4B-$5B, consensus $4.27B
- 08/08/22
- Novavax revised FY22 revenue guidance to $2B-$2.3B
- 08/08/22
- Novavax reports Q2 EPS ($6.53) vs. ($4.75) last year
- 05/09/22
- Novavax backs FY22 revenue view $4B-$5B, consensus $4.49B
- 06/27/22
- Nike sees Q1 revenue growth flat to slightly up sequentially, consensus $12.88B
- 06/27/22
- Nike sees FY23 revenue growth in low double digits, consensus $51.57B
- 06/27/22
- Nike reports Q4 EPS 90c, consensus 81c
- 06/27/22
- Notable companies reporting after market close
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line sees Q3 revenue $1.5B-$1.6B, consensus $1.88B
- 08/09/22
- Norwegian Cruise Line reports Q2 adjusted EPS ($1.14), consensus (86c)
- 08/09/22
- Micron says Q4 revenue may come in at or below low end of prior revenue guidance
- 06/30/22
- Micron reports Q3 non-GAAP EPS $2.59, consensus $2.44
- 06/30/22
- Micron sees Q4 EPS $1.63 +/- 20c, consensus $2.62
- 06/30/22
- Notable companies reporting after market close
- 07/26/22
- Microsoft sees FY23 revenue growth in double digits, consensus $225.98B
- 07/26/22
- Microsoft reports Q4 EPS $2.23, consensus $2.30
- 07/26/22
- Notable companies reporting after market close
- 06/02/22
- Microsoft lowers Q4 EPS view to $2.24-$2.32 from $2.28-$2.35, consensus $2.33
MRSN Mersana Therapeutics - 08/08/22
- Mersana Therapeutics reports Q2 EPS (55c), consensus (52c)
- 05/09/22
- Mersana Therapeutics reports Q1 EPS (59c), consensus (32c)
- 02/28/22
- Mersana Therapeutics reports Q4 EPS (68c), consensus (67c)
- 07/13/22
- ironSource backs Q2, FY22 guidance
- 05/12/22
- ironSource sees 2022 revenue $750M-$780M, consensus $810.88M
- 05/12/22
- ironSource sees Q2 revenue $180M-$185M, consensus $194.23M
- 05/12/22
- ironSource reports Q1 EPS 1c, consensus 3c
- 07/27/22
- GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year
- 04/27/22
- GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER
- 04/27/22
- GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year
- 04/13/22
- GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B
- 08/09/22
- GlobalFoundries sees Q3 adjusted EPS 59c-65c, consensus 44c
- 08/09/22
- GlobalFoundries reports Q2 adjusted EPS 58c, consensus 45c
- 08/08/22
- Notable companies reporting before tomorrow's open
- 08/08/22
- GoodRx sees Q3 revenue roughly $185M, consensus $201.4M
- 08/08/22
- GoodRx reports Q2 adjusted EPS 6c, consensus 4c
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 08/09/22
- Notable companies reporting before tomorrow's open
- 05/10/22
- Fox Corp. reports Q3 adjusted EPS 81c, consensus 88c
- 05/09/22
- Notable companies reporting before tomorrow's open
- 05/11/22
- Disney reports Q2 EPS ex-items $1.08, consensus $1.17
- 05/11/22
- Notable companies reporting after market close
- 07/28/22
- Comcast reports Q2 adjusted EPS $1.01, consensus 92c
- 07/27/22
- Notable companies reporting before tomorrow's open
- 06/20/22
- Fly Intel: Top five weekend stock stories
- 08/09/22
- Bausch Health lowers FY22 revenue view to $8.05B-$8.22B from $8.25B-$8.40B
- 08/09/22
- Bausch Health reports Q2 GAAP EPS (40c), consensus 89c
- 05/10/22
- Bausch Health sees 2022 revenue $8.25B-$8.4B, consensus $8.57B
- 05/10/22
- Bausch Health reports Q1 EPS (19c), consensus $1.29
- 06/29/22
- Bed Bath & Beyond reports Q1 adjusted EPS ($2.83), consensus ($1.39)
- 06/28/22
- Notable companies reporting before tomorrow's open
- 04/13/22
- Bed Bath & Beyond reports Q4 adjusted EPS (92c), consensus 3c
ATRA Atara Biotherapeutics - 08/08/22
- Atara Biotherapeutics reports Q2 EPS 18c, consensus (93c)
- 05/05/22
- Atara Biotherapeutics reports Q1 EPS (87c), consensus (98c)
- 02/28/22
- Atara Biotherapeutics reports Q4 EPS (96c), consensus (69c)
- 08/09/22
- AppLovin lowers FY22 revenue view to $2.84B-$3.14B from $3.14B-$3.44B
- 05/11/22
- AppLovin cuts FY22 revenue view to $3.14B-$3.44B from $3.55B-$3.85B
- 05/11/22
- AppLovin reports Q1 EPS (31c), consensus (8c)
- 02/16/22
- AppLovin sees FY22 revenue $3.55B-$3.85B, consensus $3.82B
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 08/09/22
- Vertex Energy sees 2022 capex $115M-$120M
- 08/09/22
- Vertex Energy sees Q3 total throughput 72,000-74,000 barrels per day at Mobile
- 06/14/22
- Vertex Energy names James Rhame as COO, succeeding John Strickland
- 06/14/22
- Vertex Energy appoints Alvaro Ruiz as chief strategy officer
- 08/09/22
- Verona Pharma surges after ensifentrine meets endpoint in COPD study
- 08/08/22
- Verona Pharma to announce top-line data from Phase 3 trial of Ensifentrine
- 06/09/22
- Verona Pharma completes enrollment in Phase 3 ENHANCE-1 trial
- 05/09/22
- Verona Pharma to present successful TQT analysis of ensifentrine
- 08/08/22
- Upstart Holdings trading resumes
- 08/08/22
- Upstart Holdings trading halted, news pending
- 06/08/22
- CFPB issues order to terminate Upstart 'no-action letter'
- 05/16/22
- Third Point lowers stakes in Amazon, Intuit, exits Alphabet position
- 05/16/22
- Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe
- 04/14/22
- Worldwide semiconductor revenue grew 26% in 2021, Gartner says
- 02/15/22
- DENSO to take minority stake in JASM
- 08/07/22
- Elon Musk challenges Twitter CEO to 'a public debate' on bots
- 08/07/22
- Musk says Twitter deal should not proceed if SEC filings 'materially false'
- 08/05/22
- Tesla confirms three-for-one stock split
- 08/03/22
- American Battery Metals appoints Belanger as Staff Analytical Chemist
- 07/21/22
- Tandem Diabetes acquires Capillary Biomedical, terms not disclosed
- 02/16/22
- Tandem Diabetes announces FDA clearance for t:slim X2 insulin pump
- 08/02/22
- Sysco donates $1M to Feeding America
- 07/13/22
- Sysco appoints Peereboom as EVP, president, foodservice operations
- 05/19/22
- Sysco intends to purchase up to 800 Freightliner eCascadia Class 8 tractors
- 05/14/22
- Trian exits Comcast position, increases stake in Invesco
- 08/09/22
- Ralph Lauren expects further pressure on gross margins near term
- 08/09/22
- Ralph Lauren seeing broad based strength across all regions
- 06/24/22
- Ralph Lauren announces nomination of Cupp to board of directors
- 06/24/22
- Ralph Lauren publishes 2022 Global Citizenship & Sustainability Report
- 08/08/22
- Quanterix executive chairman Krusovsky resigns
- 04/22/22
- Quanterix granted Breakthrough Device designation by the FDA for Simoa
- 03/01/22
- Quanterix, Eli Lilly enter Alzheimer's disease diagnosis collaboration
- 03/01/22
- Quanterix CEO Kevin Hrusovsky to become chairman, Masoud Toloue to succeed
- 07/25/22
- Tim China announces collaboration with Easy Joy
- 07/25/22
- Kitchen United announces $100M Series C fundraise
- 05/16/22
- Pershing Square boosts Canadian Pacific, cuts Domino's in Q1
- 05/05/22
- Regis names Matthew Doctor as CEO
- 08/08/22
- Palantir falls -12.0%
- 08/08/22
- Palantir falls -14.4%
- 08/08/22
- Palantir falls -12.2%
- 07/28/22
- Palantir announces $99.9M contract with U.S. Army Research Laboratory
- 08/02/22
- Owl Rock announces investment in Amergin Asset Management
- 06/21/22
- Franchise Group announces sale of W.S. Badcock corporation distribution centers
- 04/13/22
- Arko Corp.'s GPM secures $1.15B real property commitment from Oak Street
- 02/16/22
- Blue Owl Capital to acquire Wellfleet Credit Partners from Littlejohn & Co.
- $40.08 /
-17.25 (-30.09%) - 08/08/22
- Novavax drops 30% to $39.59 after cutting FY22 revenue outlook
- 08/08/22
- Novavax trading resumes
- 08/08/22
- Novavax trading halted, news pending
- 08/04/22
- Novavax initiates Phase 2b&3 trial of COVID-19 vaccine in younger children
- 07/27/22
- CarGurus appoints Javier Zamora as general counsel
- 07/19/22
- Skechers down 4% as short-seller Spruce Point sees 30%-50% downside risk
- 06/27/22
- Nike says taking 'cautious approach' to greater China in FY23
- 06/27/22
- Nike says digital now represents 24% of brand revenue
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line: Booking trends for FY23 remain 'positive'
- 08/09/22
- Norwegian Cruise Line 'encouraged' by continued strong consumer demand
- 08/09/22
- Norwegian Cruise Line expects to report a net loss for Q3
- 08/08/22
- Norwegian Cruise Line revises vaccination, testing protocols
- 08/09/22
- Micron to invest $40B to build memory manufacturing in phases in the U.S.
- 07/29/22
- Micron intends to bring memory manufacturing to the U.S.
- 07/26/22
- Micron ships 232-layer NAND
- 07/21/22
- Western Digital, Micron trade lower after Seagate earnings miss
MRSN Mersana Therapeutics - 08/08/22
- Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056
- 08/08/22
- Mersana Therapeutics trading resumes
- 08/08/22
- Mersana Therapeutics trading halted, news pending
- 05/23/22
- Mersana Therapeutics director Hack buys 216K shares of stock
- 08/08/22
- GSK, IQVIA launch Vaccine Track platform
- 07/29/22
- ViiV Healthcare presents five-year data at AIDS 2022 on fostemsavir
- 07/28/22
- ViiV Healthcare announces data from unblinded phase of HPTN 084 study
- 08/08/22
- GlobalFoundries, Qualcomm extend semiconductor manufacturing agreement
- 07/11/22
- STMicroelectronics, GlobalFoundries to create chip manufacturing facility
- 05/19/22
- GlobalFoundries, Motorola announce strategic agreement for chip supply
- 05/03/22
- GlobalFoundries awarded $117M DoD chip supply deal
- 08/09/22
- GoodRx rallies after saying grocer issue recently addressed
- 05/17/22
- GoodRx announces strategic relationship with RxVantage
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 08/08/22
- Carlyle Group CEO Kewsong Lee to step down, Bill Conway to be interim CEO
- 07/12/22
- Madison Dearborn Partners to acquire majority stake in Unison from Carlyle
- 05/16/22
- Carlyle to acquire ManTech for $96 per share in $4.2B enterprise value deal
- 05/09/22
- White Mountains to sell NSM Insurance Group to Carlyle Group
- 08/01/22
- Bausch Health credit cut at S&P on 'much more challenging' prospects
- 07/28/22
- Bausch Health trading resumes
- 07/28/22
- Bausch Health to appeal expected court decision on certain Xifaxan patents
- 07/28/22
- Bausch Health 'disappointed' with oral order on Xifaxan patents, plans to appeal
- 08/03/22
- Bed Bath & Beyond down 3% to $5.62 after Bloomberg report on credit talks
- 07/21/22
- Freeman Capital discloses 6.21% stake in Bed Bath & Beyond
- 07/07/22
- Bed Bath & Beyond interim CEO Sue Gove buys 50,000 shares of common stock
- 07/04/22
- Fly Intel: Top five weekend stock stories
- 08/09/22
- Avaya says board committee investigating whistleblower letter
- 08/09/22
- Avaya notes 'substantial doubt' about ability to continue as a going concern
- 07/29/22
- Avaya appoints Masarek as President, CEO
- 06/27/22
- Avaya announces $600M financing
ATRA Atara Biotherapeutics - 07/12/22
- Atara Biotherapeutics not to expand sample size in ATA188 Ph2 study
- 06/05/22
- Atara announces clinical data from ongoing tab-cel European Multicenter EAP
- 05/19/22
- Atara Biotherapeutics down 14% at $4.44 after announcing end of Bayer deal
- 05/19/22
- Atara provides update on Bayer collaboration
- 08/09/22
- ironSource drops 10% as AppLovin's Unity bid contingent on ironSource deal exit
- 08/09/22
- AppLovin submits proposal to combine with Unity
- 08/09/22
- AppLovin says proposal to combine would value Unity at $58.85 per share
- 08/09/22
- AppLovin announces non-binding proposal to combine with Unity Software
- 08/03/22
- Microsoft says Teams now optimized for Mac computers
- 07/28/22
- Apple says 'constantly surveilling' the market for potential acquisitions
- 07/28/22
- Apple expects Q4 revenue to accelerate y/y
- 07/28/22
- Apple says response to iPhone 13 'continues to be strong'
- 08/09/22 Oppenheimer
- AppLovin price target lowered to $65 from $74 at Oppenheimer
- 08/08/22 Credit Suisse
- AppLovin price target lowered to $80 from $100 at Credit Suisse
- 08/03/22 Stifel
- AppLovin price target lowered to $50 from $80 at Stifel
- 07/07/22 Citi
- AppLovin price target lowered to $62 from $68 at Citi
- 08/02/22 Stifel
- Unity price target lowered to $50 from $60 at Stifel
- 07/14/22 DA Davidson
- Unity price target lowered to $60 from $85 at DA Davidson
- 07/14/22 Needham
- ironSource downgraded to Hold from Buy at Needham
- 08/09/22 Raymond James
- Micron downgraded to Outperform at Raymond James on near-term headwinds
- 08/09/22 Raymond James
- Micron downgraded to Outperform from Strong Buy at Raymond James
- 07/27/22 Baird
- CHIPS Act could have deflationary impact on semiconductors, says Baird
- 07/22/22 Morgan Stanley
- Micron downgraded to Underweight from Equal Weight at Morgan Stanley
- 07/20/22 Deutsche Bank
- GlobalFoundries price target lowered to $55 from $70 at Deutsche Bank
- 07/11/22 Susquehanna
- GlobalFoundries price target lowered to $75 from $85 at Susquehanna
- 06/29/22 BofA
- GlobalFoundries price target lowered to $57 from $75 at BofA
- $40.08 /
-17.25 (-30.09%) - 08/09/22 Cowen
- Novavax price target lowered to $110 from $150 at Cowen
- 07/22/22 B. Riley
- Novavax price target lowered to $171 from $181 at B. Riley
- 06/08/22 B. Riley
- B. Riley sees front line status for Novavax vaccine as mRNA alternative
- 06/08/22 Cowen
- Novavax positive advisory vote removes major overhang, says Cowen
- 08/05/22 Credit Suisse
- Ralph Lauren price target lowered to $120 from $130 at Credit Suisse
- 08/01/22 Deutsche Bank
- Ralph Lauren price target lowered to $99 from $101 at Deutsche Bank
- 07/21/22 Goldman Sachs
- Ralph Lauren price target lowered to $78 from $85 at Goldman Sachs
- 07/15/22 UBS
- Ralph Lauren price target lowered to $129 from $162 at UBS
- 08/09/22 Morgan Stanley
- Palantir price target lowered to $11 from $13 at Morgan Stanley
- 08/09/22 Citi
- Palantir price target lowered to $6 from $7 at Citi
- 08/09/22 Deutsche Bank
- Palantir downgraded to Sell from Hold at Deutsche Bank
- 08/08/22 Jefferies
- Palantir price target lowered to $12 from $13 at Jefferies
- 08/09/22 Baird
- Baird downgrades Bed Bath & Beyond to sell after 86% two-day rally
- 08/09/22 Baird
- Bed Bath & Beyond downgraded to Underperform from Neutral at Baird
- 08/08/22 Odeon Capital
- Bed Bath & Beyond cut to Hold at Odeon Capital following doubling in a week
- 08/08/22 Odeon Capital
- Bed Bath & Beyond downgraded to Hold from Buy at Odeon Capital
- 08/09/22 Exane BNP Paribas
- Nike downgraded to Neutral at Exane BNP Paribas on concerns about FY25 targets
- 08/09/22 Exane BNP Paribas
- Nike downgraded to Neutral from Outperform at Exane BNP Paribas
- 07/25/22 Piper Sandler
- Nike assumed with a Neutral at Piper Sandler
- 07/21/22 KeyBanc
- KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view
- 08/09/22 Argus
- Restaurant Brands upgraded to Buy at Argus on earnings upside
- 08/09/22 Argus
- Restaurant Brands upgraded to Buy from Hold at Argus
- 08/05/22 Baird
- Restaurant Brands price target raised to $63 from $56 at Baird
- 08/05/22 Deutsche Bank
- Restaurant Brands price target raised to $70 from $64 at Deutsche Bank
- 08/09/22 Wells Fargo
- Tandem Diabetes downgraded to Underweight from Overweight at Wells Fargo
- 08/04/22 Craig-Hallum
- Tandem Diabetes price target lowered to $105 from $156 at Craig-Hallum
- 08/04/22 Lake Street
- Tandem Diabetes price target lowered to $150 from $200 at Lake Street
- 08/04/22 Cowen
- Tandem Diabetes price target lowered to $107 from $141 at Cowen
- 07/11/22 JPMorgan
- Blue Owl Capital initiated with a Neutral at JPMorgan (Thursday)
- 06/08/22 JMP Securities
- Blue Owl Capital initiated with an Outperform at JMP Securities
- 01/24/22 BofA
- Blue Owl Capital initiated with a Buy at BofA
- 01/24/22 BofA
- Blue Owl Capital initiated with a Buy at BofA
- 07/29/22 Craig-Hallum
- Avaya downgraded to Hold from Buy at Craig-Hallum
- 07/29/22 Craig-Hallum
- Avaya downgraded to Hold from Buy at Craig-Hallum
- 07/26/22 Barclays
- Avaya price target lowered to $2 from $5 at Barclays
- 06/06/22 Citi
- Avaya price target lowered to $6 from $9 at Citi
- 08/08/22 Canaccord
- Tesla price target raised to $881 from $815 at Canaccord
- 08/05/22 Susquehanna
- Susquehanna downgrades Twitter on 'uncertainty and disruption' from takeover
- 08/03/22 Morgan Stanley
- Tesla exposed to both risk and opportunity of battery race, says Morgan Stanley
- 08/02/22 Citi
- Tesla price target raised to $424 from $375 at Citi
- 08/09/22 Jefferies
- Carlyle Group downgraded to Hold from Buy at Jefferies
- 07/29/22 Evercore ISI
- Carlyle Group upgraded to Outperform from In Line at Evercore ISI
- 07/13/22 Deutsche Bank
- Carlyle Group price target lowered to $56 from $64 at Deutsche Bank
- 06/08/22 JMP Securities
- Carlyle Group initiated with an Outperform at JMP Securities
- 08/03/22 Northland
- AMD price target raised to $105 from $95 at Northland
- 07/14/22 Susquehanna
- TSMC price target lowered to $88 from $90 at Susquehanna
- 07/12/22 Citi
- Citi sees estimate upside, 'upbeat' Q2 from TSMC
- 06/21/22 Loop Capital
- TSMC initiated with a Buy at Loop Capital
- 08/08/22 B. Riley
- B. Riley thinks Globalstar's mystery satellite capacity customer is Apple
- 08/05/22 BMO Capital
- Skyworks price target raised to $135 from $120 at BMO Capital
- 08/05/22 Needham
- Meta Platforms outlook made worse by Apple's AdTech platform, says Needham
- 08/03/22 Morgan Stanley
- Apple App Store growth decelerated in July, says Morgan Stanley
- 06/17/22 Wedbush
- Verona Pharma price target lowered to $18 from $25 at Wedbush
- 09/13/21
- Fly Intel: Top five analyst initiations
- 09/13/21 H.C. Wainwright
- Verona Pharma initiated with a Buy at H.C. Wainwright
MRSN Mersana Therapeutics - 08/09/22 Baird
- Mersana Therapeutics price target raised to $20 from $18 at Baird
- 05/10/22 Baird
- Mersana Therapeutics price target lowered to $18 from $23 at Baird
- 05/09/22 H.C. Wainwright
- Mersana price target lowered to $19 from $24 at H.C. Wainwright
- 11/10/21 Baird
- Mersana Therapeutics price target lowered to $23 from $30 at Baird
- 08/08/22 UBS
- GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
- 08/05/22 Morgan Stanley
- GSK plc resumed with an Equal Weight at Morgan Stanley
- 07/21/22 Citi
- GSK plc resumed with a Neutral at Citi
ATRA Atara Biotherapeutics - 07/20/22 Citi
- Atara Biotherapeutics downgraded to Sell from Neutral at Citi
- 07/13/22 Canaccord
- Atara Biotherapeutics price target lowered to $50 from $67 at Canaccord
- 07/13/22 Stifel
- Stifel downgrades Atara Biotherapeutics to Hold following ATA188 analysis
- 07/13/22 Stifel
- Atara Biotherapeutics downgraded to Hold from Buy at Stifel
- 08/09/22 Cowen
- Quanterix downgraded to Market Perform from Outperform at Cowen
- 08/09/22 SVB Securities
- Quanterix downgraded to Market Perform from Outperform at SVB Securities
- 05/11/22 Cowen
- Quanterix price target lowered to $38 from $60 at Cowen
- 03/15/22 BTIG
- Quanterix price target lowered to $60 from $92 at BTIG
- 07/07/22 Oppenheimer
- Vertex Energy initiated with an Outperform at Oppenheimer
- 06/08/22 Stifel
- Vertex Energy price target raised to $20 from $14 at Stifel
- 12/01/21 Credit Suisse
- Vertex Energy initiated with an Outperform at Credit Suisse
- 11/09/21 Craig-Hallum
- Vertex Energy price target lowered to $18 from $25 at Craig-Hallum
- 07/29/22 RBC Capital
- Bausch Health downgraded to Sector Perform from Outperform at RBC Capital
- 07/29/22 RBC Capital
- Bausch Health downgraded to Sector Perform from Outperform at RBC Capital
- 07/28/22 Truist
- Bausch Health downgraded to Hold from Buy at Truist
- 07/28/22 Stifel
- Stifel puts Bausch rating under review amid 'significant confusion'
NCLH Norwegian Cruise Line - 06/29/22 Barclays
- Barclays initiates cruise line space with Royal Caribbean top pick
- 06/28/22 Barclays
- Norwegian Cruise Line initiated with an Equal Weight at Barclays
- 06/21/22 Deutsche Bank
- Norwegian Cruise Line price target lowered to $17 from $23 at Deutsche Bank
- 06/09/22 Susquehanna
- Norwegian Cruise Line initiated with a Positive at Susquehanna
- 08/09/22 Morgan Stanley
- Upstart origination volume may have peaked, says Morgan Stanley
- 08/09/22 Stephens
- Upstart price target lowered to $23 from $28 at Stephens
- 07/22/22 Morgan Stanley
- Berkshire Hills halting additions of new Upstart loans, says Morgan Stanley
- 07/18/22 Piper Sandler
- Upstart price target lowered to $25 from $44 at Piper Sandler
- 08/09/22 Goldman Sachs
- Goldman Sachs raises GoodRx price target to $10 amid grocer issue resolution
- 08/09/22 RBC Capital
- GoodRx price target raised to $11 from $6.50 at RBC Capital
- 08/09/22 Barclays
- GoodRx price target raised to $13 from $12 at Barclays
- 07/20/22 Barclays
- GoodRx price target lowered to $12 from $15 at Barclays
- 06/29/22 Barclays
- Sysco price target raised to $102 from $97 at Barclays
- 06/09/22 Barclays
- Sysco price target lowered to $97 from $102 at Barclays
- 05/26/22 JPMorgan
- Sysco upgraded to Overweight after recent pullback at JPMorgan
- 05/26/22 JPMorgan
- Sysco upgraded to Overweight from Neutral at JPMorgan
- 08/09/22
- Vertex Energy reports Q2 EPS (98c) vs. (38c) last year
- 05/10/22
- Vertex Energy sees FY23 adjusted EBITDA $425M-$450M
- 05/10/22
- Vertex Energy sees FY22 adjusted EBITDA $340M-$360M
- 05/10/22
- Vertex Energy reports Q1 EPS (8c), consensus (14c)
- 08/09/22
- Verona Pharma reports Q2 EPS (4c), consensus (38c)
- 08/08/22
- Upstart sees Q3 revenue $170M, consensus $248.92M
- 08/08/22
- Upstart reports Q2 adjusted EPS 1c, consensus 10c
- 08/08/22
- Notable companies reporting after market close
- 07/07/22
- Upstart cuts Q2 revenue view to $228M from $295M-$305M, consensus $297.68M
- 07/13/22
- Unity Software sees Q2 results 'slightly higher' than top end of guidance range
- 07/13/22
- Unity Software cuts FY22 revenue view to $1.3B-$1.35B from $1.35B-$1.425B
- 05/10/22
- Unity Software cuts FY22 revenue view to $1.35B-$1.425B, consensus $1.5B
- 05/10/22
- Unity Software sees Q2 revenue $290M-$295M, consensus $360.97M
- 07/14/22
- TSMC sees Q3 revenue $19.8B-$20.6B, consensus $19.21B
- 07/14/22
- TSMC reports Q2 EPS $1.55, consensus $1.47
- 04/14/22
- TSMC sees Q2 revenue $17.6B-$18.2B, consensus $18B
- 04/14/22
- TSMC reports Q1 EPS $1.40, consensus $1.33
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 04/20/22
- Tesla reports Q1 EPS $3.22, consensus $2.26
- 04/20/22
- Notable companies reporting after market close
- 08/03/22
- Tandem Diabetes cuts FY22 revenue view to $835M-$845 from $850M-$865M
- 08/03/22
- Tandem Diabetes reports Q2 EPS (24c), consensus 2c
- 05/04/22
- Tandem Diabetes raises FY22 revenue view to $850M-$865M, consensus $846.54M
- 05/04/22
- Tandem Diabetes reports Q1 EPS (23c), consensus (7c)
- 08/09/22
- Sysco reaffirms FY24 adjusted EPS guidance 30% higher than FY19
- 08/09/22
- Sysco prepared to generate sales growth of at least 10% in 2023
- 08/09/22
- Sysco sees FY23 adjusted EPS $4.09 - $4.39
- 08/09/22
- Sysco reports Q4 adjusted EPS $1.15 vs 71c last year
- 08/09/22
- Ralph Lauren backs FY23 revenue view up high single digits, consensus $6.38B
- 08/09/22
- Ralph Lauren sees Q2 revenue up 11%, consensus $1.58B
- 08/09/22
- Ralph Lauren reports Q1 adjusted EPS $1.88 vs. $2.29 last year
- 08/08/22
- Quanterix reports Q2 revenue $23.5M, consensus $30.1M
- 05/10/22
- Quanterix reports Q1 net loss $18.2M vs.$10.1M loss last year
- 03/01/22
- Quanterix reports Q4 revenue $30.29M, consensus $28.49M
- 08/04/22
- Restaurant Brands reports Q2 EPS 76c, consensus 73c
- 05/03/22
- Restaurant Brands reports Q1 adjusted EPS 64c, consensus 62c
- 02/15/22
- Restaurant Brands reports Q4 EPS 74c, consensus 69c
- 02/14/22
- Notable companies reporting before tomorrow's open
- 08/08/22
- Palantir sees FY22 revenue $1.9B - $1.902B , consensus $1.96B
- 08/08/22
- Palantir sees Q3 revenue $474M - $475M , consensus $506.88M
- 08/08/22
- Palantir reports Q2 EPS (9c) vs. (7c) last year
- 05/09/22
- Palantir sees Q2 revenue base case $470M, consensus $483.84M
- 08/04/22
- Blue Owl Capital reports Q2 EPS 0c vs. ($1.23) a year ago
- 02/17/22
- Blue Owl Capital reports Q4 adjusted EPS 12c, consensus 11c
- $40.08 /
-17.25 (-30.09%) - 08/08/22
- Novavax cuts FY22 revenue view to $2B-$2.3B from $4B-$5B, consensus $4.27B
- 08/08/22
- Novavax revised FY22 revenue guidance to $2B-$2.3B
- 08/08/22
- Novavax reports Q2 EPS ($6.53) vs. ($4.75) last year
- 05/09/22
- Novavax backs FY22 revenue view $4B-$5B, consensus $4.49B
- 06/27/22
- Nike sees Q1 revenue growth flat to slightly up sequentially, consensus $12.88B
- 06/27/22
- Nike sees FY23 revenue growth in low double digits, consensus $51.57B
- 06/27/22
- Nike reports Q4 EPS 90c, consensus 81c
- 06/27/22
- Notable companies reporting after market close
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line sees Q3 revenue $1.5B-$1.6B, consensus $1.88B
- 08/09/22
- Norwegian Cruise Line reports Q2 adjusted EPS ($1.14), consensus (86c)
- 08/09/22
- Micron says Q4 revenue may come in at or below low end of prior revenue guidance
- 06/30/22
- Micron reports Q3 non-GAAP EPS $2.59, consensus $2.44
- 06/30/22
- Micron sees Q4 EPS $1.63 +/- 20c, consensus $2.62
- 06/30/22
- Notable companies reporting after market close
MRSN Mersana Therapeutics - 08/08/22
- Mersana Therapeutics reports Q2 EPS (55c), consensus (52c)
- 05/09/22
- Mersana Therapeutics reports Q1 EPS (59c), consensus (32c)
- 02/28/22
- Mersana Therapeutics reports Q4 EPS (68c), consensus (67c)
- 07/27/22
- GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year
- 04/27/22
- GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER
- 04/27/22
- GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year
- 04/13/22
- GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B
- 08/09/22
- GlobalFoundries sees Q3 adjusted EPS 59c-65c, consensus 44c
- 08/09/22
- GlobalFoundries reports Q2 adjusted EPS 58c, consensus 45c
- 08/08/22
- Notable companies reporting before tomorrow's open
- 08/08/22
- GoodRx sees Q3 revenue roughly $185M, consensus $201.4M
- 08/08/22
- GoodRx reports Q2 adjusted EPS 6c, consensus 4c
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 04/29/22
- Carlyle Group reports Q1 EPS 74c vs. 58c last year
- 08/09/22
- Bausch Health lowers FY22 revenue view to $8.05B-$8.22B from $8.25B-$8.40B
- 08/09/22
- Bausch Health reports Q2 GAAP EPS (40c), consensus 89c
- 05/10/22
- Bausch Health sees 2022 revenue $8.25B-$8.4B, consensus $8.57B
- 05/10/22
- Bausch Health reports Q1 EPS (19c), consensus $1.29
- 06/29/22
- Bed Bath & Beyond reports Q1 adjusted EPS ($2.83), consensus ($1.39)
- 06/28/22
- Notable companies reporting before tomorrow's open
- 04/13/22
- Bed Bath & Beyond reports Q4 adjusted EPS (92c), consensus 3c
- 08/09/22
- Avaya sees Q3 non-GAAP EPS 24c, consensus 5c
- 07/28/22
- Avaya sees Q3 revenue $575M-$580M, below previous guidance of $685M-$700M
- 05/10/22
- Avaya sees FY22 non-GAAP EPS $2.09-$2.25, consensus $2.80
- 05/10/22
- Avaya sees Q3 non-GAAP EPS 48c-56c, consensus 84c
ATRA Atara Biotherapeutics - 08/08/22
- Atara Biotherapeutics reports Q2 EPS 18c, consensus (93c)
- 05/05/22
- Atara Biotherapeutics reports Q1 EPS (87c), consensus (98c)
- 02/28/22
- Atara Biotherapeutics reports Q4 EPS (96c), consensus (69c)
- 08/09/22
- AppLovin lowers FY22 revenue view to $2.84B-$3.14B from $3.14B-$3.44B
- 05/11/22
- AppLovin cuts FY22 revenue view to $3.14B-$3.44B from $3.55B-$3.85B
- 05/11/22
- AppLovin reports Q1 EPS (31c), consensus (8c)
- 02/16/22
- AppLovin sees FY22 revenue $3.55B-$3.85B, consensus $3.82B
- 07/28/22
- Apple reports Q3 EPS $1.20, consensus $1.16
- 07/28/22
- Notable companies reporting after market close
- 04/28/22
- Apple says y/y Q3 revenue growth to be impacted by COVID
- 04/28/22
- Apple reports Q2 EPS $1.52, consensus $1.43
|
Options
|
Unusual total active… Unusual total active option classes on open include: UiPath (PATH), Express (EXPR), Amyris (AMRS), Enovix (ENVX), Lam Research (LRCX), Bed Bath & Beyond (BBBY), Norwegian Cruise Lines (NCLH), Tilray (TLRY), Micron (MU), and Nokia (NOK). ShowHide Related Items >><< - 08/04/22
- Tilray's Breckenridge Distillery announces two new Mile High Bourbon Blends
- 08/03/22
- Tilray announces US distribution agreement with Southern Glazer's Wine & Spirit
- 07/19/22
- Tilray Medical launches cannabis education platform 'WeCare-MedicalCannabis'
- 07/14/22
- Tilray announces 'Wild West' lineup from CANACA brand
- 06/27/22
- UiPath to reduce about 5% of company's global workforce under restructuring
- 06/09/22
- Cathie Wood's ARK Investment bought 383.8K shares of UiPath today
- 06/08/22
- Cathie Wood's ARK Investment bought 329.8K shares of UiPath today
- 06/07/22
- Cathie Wood's ARK Investment bought 96K shares of UiPath today
- 08/03/22
- Keysight, Nokia collaborate on public 800GE test
- 07/28/22
- Nokia wins five-year global 4G and 5G deal from AST SpaceMobile
- 07/28/22
- AST SpaceMobile signs five-year 5G deal with Nokia
- 07/21/22
- Nokia rises 6.7%
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line: Booking trends for FY23 remain 'positive'
- 08/09/22
- Norwegian Cruise Line 'encouraged' by continued strong consumer demand
- 08/09/22
- Norwegian Cruise Line expects to report a net loss for Q3
- 08/08/22
- Norwegian Cruise Line revises vaccination, testing protocols
- 08/09/22
- Micron to invest $40B to build memory manufacturing in phases in the U.S.
- 07/29/22
- Micron intends to bring memory manufacturing to the U.S.
- 07/26/22
- Micron ships 232-layer NAND
- 07/21/22
- Western Digital, Micron trade lower after Seagate earnings miss
- 07/12/22
- Lam Research, Entegris, Gelest partner for EUV dry resist technology ecosystem
- 05/30/22
- Fly Intel: Top five weekend stock stories
- 05/11/22
- Lam Research announces $5B share repurchase program
- 04/14/22
- Worldwide semiconductor revenue grew 26% in 2021, Gartner says
- 03/25/22
- Express appoints Jason Judd as CFO
- 03/09/22
- Express sees FY22 comparable sales up 7%-9%
- 03/09/22
- Express sees Q1 comparable sales up 25%-30% year-over-year
- 07/28/22
- Enovix enters distribution agreement with EDOM Technology
- 07/12/22
- Enovix announces shipment of battery packs
- 06/28/22
- Enovix Mobility announces it has broadened leadership team
- 06/22/22
- Enovix to join Russell 2000, 3000 Indexes
- 08/03/22
- Bed Bath & Beyond down 3% to $5.62 after Bloomberg report on credit talks
- 07/21/22
- Freeman Capital discloses 6.21% stake in Bed Bath & Beyond
- 07/07/22
- Bed Bath & Beyond interim CEO Sue Gove buys 50,000 shares of common stock
- 07/04/22
- Fly Intel: Top five weekend stock stories
- 08/09/22
- Amyris reaffirms FY22 consumer revenue view up 150%
- 06/23/22
- Amyris begins fermentation at new plant in Barra Bonita, Brazil
- 04/11/22
- Amyris begins commissioning of new fermentation plant in Barra Bonita, Brazil
- 07/07/22 Canaccord
- UiPath assumed with a Buy at Canaccord
- 06/27/22 Truist
- Truist keeps $45 target on UiPath after restructuring annoucement
- 06/02/22 BMO Capital
- UiPath price target lowered to $21 from $29 at BMO Capital
- 06/02/22 Truist
- UiPath price target lowered to $45 from $55 at Truist
- 06/24/22 JPMorgan
- Amyris initiated with a Neutral at JPMorgan
- 05/25/22 Piper Sandler
- Amyris initiated with a Neutral at Piper Sandler
- 05/13/22 HSBC
- Amyris earnings selloff overdone, says HSBC
- 03/02/22 Cowen
- Amyris assumed with an Outperform at Cowen
- 08/08/22 Loop Capital
- Enovix initiated with a Buy at Loop Capital
- 08/05/22 JPMorgan
- Enovix initiated with an Overweight at JPMorgan
- 06/24/22 Cowen
- Enovix price target lowered to $20 from $24 at Cowen
- 05/03/22 Cowen
- Enovix order 'perhaps' from Apple or Google, says Cowen
- 07/28/22 DA Davidson
- Lam Research price target lowered to $550 from $575 at DA Davidson
- 07/28/22 Wells Fargo
- Lam Research price target raised to $475 from $460 at Wells Fargo
- 07/28/22 Cowen
- Lam Research price target lowered to $620 from $800 at Cowen
- 07/28/22 Mizuho
- Lam Research price target lowered to $650 from $675 at Mizuho
- 08/09/22 Baird
- Baird downgrades Bed Bath & Beyond to sell after 86% two-day rally
- 08/09/22 Baird
- Bed Bath & Beyond downgraded to Underperform from Neutral at Baird
- 08/08/22 Odeon Capital
- Bed Bath & Beyond cut to Hold at Odeon Capital following doubling in a week
- 08/08/22 Odeon Capital
- Bed Bath & Beyond downgraded to Hold from Buy at Odeon Capital
NCLH Norwegian Cruise Line - 06/29/22 Barclays
- Barclays initiates cruise line space with Royal Caribbean top pick
- 06/28/22 Barclays
- Norwegian Cruise Line initiated with an Equal Weight at Barclays
- 06/21/22 Deutsche Bank
- Norwegian Cruise Line price target lowered to $17 from $23 at Deutsche Bank
- 06/09/22 Susquehanna
- Norwegian Cruise Line initiated with a Positive at Susquehanna
- 07/29/22 Cowen
- Tilray price target lowered to $9 from $23 at Cowen
- 07/29/22 Benchmark
- Tilray cut to Sell at Benchmark on continued deterioration in core business
- 07/29/22 Benchmark
- Tilray downgraded to Sell from Hold at Benchmark
- 07/15/22 Roth Capital
- Tilray price target lowered to $4 from $8 at Roth Capital
- 07/27/22 Baird
- CHIPS Act could have deflationary impact on semiconductors, says Baird
- 07/22/22 Morgan Stanley
- Micron downgraded to Underweight from Equal Weight at Morgan Stanley
- 07/05/22 Fox Advisors
- Micron downgraded to Equal Weight from Overweight at Fox Advisors
- 07/05/22 Benchmark
- Seagate price target lowered to $93 from $100 at Benchmark
- 07/27/22 Northland
- Calix price target raised to $55 from $50 at Northland
- 07/25/22 Credit Suisse
- Nokia price target lowered to EUR 5.45 from EUR 5.75 at Credit Suisse
- 07/22/22 Deutsche Bank
- Nokia price target raised to EUR 6 from EUR 5.50 at Deutsche Bank
- 07/22/22 Kepler Cheuvreux
- Nokia downgraded to Hold from Buy at Kepler Cheuvreux
- 07/28/22
- Tilray reports Q4 EPS (90c) vs. 38c last year
- 04/06/22
- Tilray reports Q3 EPS 9c vs. ($1.03) last year
- 06/27/22
- UiPath increasing non-GAAP operating income guidance for FY23
- 06/27/22
- UiPath backs Q2 revenue view of $229M-$231M, consensus $231.05M
- 06/01/22
- UiPath sees FY23 revenue $1.085B-$1.09B, consensus $1.07B
- 06/01/22
- UiPath sees Q1 revenue $229M-$231M, consensus $227.14M
- 07/21/22
- Nokia backs FY22 revenue view EUR 22.6B-EUR 23.8B
- 07/21/22
- Nokia reports Q2 comparable EPS EUR 0.10 vs EUR 0.09 last year
- 04/28/22
- Nokia raises FY22 revenue view to EUR 22.9B-EUR 24.1B from EUR 22.6B-EUR 23.8B
- 04/28/22
- Nokia reports Q1 comparable EPS EUR 0.07 vs EUR 0.07 last year
NCLH Norwegian Cruise Line - 08/09/22
- Norwegian Cruise Line sees Q3 revenue $1.5B-$1.6B, consensus $1.88B
- 08/09/22
- Norwegian Cruise Line reports Q2 adjusted EPS ($1.14), consensus (86c)
- 08/08/22
- Notable companies reporting before tomorrow's open
- 08/09/22
- Micron says Q4 revenue may come in at or below low end of prior revenue guidance
- 06/30/22
- Micron reports Q3 non-GAAP EPS $2.59, consensus $2.44
- 06/30/22
- Micron sees Q4 EPS $1.63 +/- 20c, consensus $2.62
- 06/30/22
- Notable companies reporting after market close
- 07/27/22
- Lam Research sees Q1 EPS $8.75-$10.25, consensus $8.82
- 07/27/22
- Lam Research reports Q4 EPS $8.83, consensus $7.32
- 07/27/22
- Notable companies reporting after market close
- 04/20/22
- Lam Research sees Q1 EPS 7.25 +/- 75c , consensus $8.24
- 05/25/22
- Express sees FY22 adjusted EPS 14c-20c vs. (23c) in 2021
- 05/25/22
- Express sees Q2 comparable sales up in mid-single digits year-over-year
- 05/25/22
- Express reports Q1 adjusted EPS (10c) vs. (55c) a year ago
- 03/09/22
- Express reports Q4 EPS 11c, consensus (2c)
- 05/11/22
- Enovix reports Q1 EPS (16c), consensus (16c)
- 03/03/22
- Enovix reports Q4 EPS (60c), consensus (15c)
- 06/29/22
- Bed Bath & Beyond reports Q1 adjusted EPS ($2.83), consensus ($1.39)
- 06/28/22
- Notable companies reporting before tomorrow's open
- 04/13/22
- Bed Bath & Beyond reports Q4 adjusted EPS (92c), consensus 3c
- 08/09/22
- Amyris reports Q2 GAAP EPS (34c), consensus (26c)
- 04/11/22
- NJ approves sale of retail marijuana from seven dispensaries, Bloomberg says
- 04/01/22
- U.S. House backs federal marijuana legalization bill, Marijuana Moment reports
- 03/24/22
- House to vote on marijuana legalization bill next week, Marijuana Moment says
- 02/19/22
- Might be the time to plug into Nokia's stock, Barron's says
NCLH Norwegian Cruise Line - 07/02/22
- Not the time to bottom-fish cruise operator stocks, Barron's says
- 05/02/22
- Fincantieri, Norwegian in discussions over $4B cruise ship order, Reuters says
- 03/02/22
- Carnival, Norwegian update mask policy, now optional for most, WSJ reports
- 07/28/22
- House passes bill giving $52B to U.S. chipmakers, Bloomberg reports
- 07/19/22
- New bill to provide $52B boost to US semiconductor manufacturing, WSJ reports
- 06/13/22
- Micron to commercialize 1-gamma EUV process in Taiwan in 2024, DigiTimes says
- 07/27/22
- Senate pushes bipartisan chip bill to House to boost U.S, production, CNN says
- 05/28/22
- Alphabet, Meta among bargain stocks to buy now, Barron's says
- 05/09/22
- U.S. considering broader crackdown on Chinese chipmakers, Information reports
- 08/03/22
- Bed Bath & Beyond weighing private loans, Bloomberg reports
- 08/03/22
- Bed Bath & Beyond in talks with private credit providers, Bloomberg says
- 07/02/22
- Bed Bath & Beyond remodeling not working, Barron's says
- 06/29/22
- Ryan Cohen happy with Bed Bath & Beyond CEO exit, CNBC reports
- 08/05/22
- Sell these stocks now, proven algorithm says
- 08/04/22
- Here's What You Missed in Cannabis This Week
- 07/29/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/28/22
- Rising High: Exclusive talk with vertically-integrated MSO Greenlight
- 06/27/22
- What You Missed On Wall Street On Monday
- 06/27/22
- What You Missed On Wall Street This Morning
- 06/02/22
- What You Missed On Wall Street On Thursday
- 06/02/22
- What You Missed On Wall Street This Morning
- 07/21/22
- What You Missed On Wall Street On Thursday
- 07/21/22
- What You Missed On Wall Street This Morning
- 04/12/22
- What You Missed On Wall Street On Tuesday
- 04/12/22
- What You Missed On Wall Street This Morning
NCLH Norwegian Cruise Line - 08/09/22
- Fly Intel: Pre-market Movers
- 04/13/22
- What You Missed On Wall Street On Wednesday
- 04/13/22
- What You Missed On Wall Street This Morning
- 03/17/22
- What You Missed On Wall Street On Thursday
- 07/22/22
- What You Missed On Wall Street On Friday
- 07/22/22
- What You Missed On Wall Street This Morning
- 07/22/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/27/22
- Fly Intel: After-Hours Movers
- 07/25/22
- What You Missed On Wall Street On Monday
- 07/25/22
- What You Missed On Wall Street This Morning
- 07/25/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/25/22
- What You Missed On Wall Street On Wednesday
- 05/25/22
- What You Missed On Wall Street This Morning
- 05/25/22
- Fly Intel: Pre-market Movers
- 03/09/22
- Fly Intel: Pre-market Movers
- 07/29/22
- Sell these stocks now, proven algorithm says
- 05/03/22
- What You Missed On Wall Street On Tuesday
- 05/03/22
- What You Missed On Wall Street This Morning
- 03/04/22
- What You Missed On Wall Street On Friday
- 08/07/22
- Short Report: Bed Bath Beyond in short-squeeze spotlight
- 08/03/22
- What You Missed On Wall Street On Wednesday
- 07/23/22
- Short Report: Revlon shorts recede, stock retreats as buyout news fades
- 07/09/22
- Short Report: Carvana, Bed Bath Beyond short interest continues to grow
- 06/23/22
- What You Missed On Wall Street On Thursday
- 06/23/22
- What You Missed On Wall Street This Morning
- 08/01/22
- Largest borrow rate increases among liquid names
- 07/27/22
- Unusually active option classes on open July 27th
- 07/15/22
- Unusually active option classes on open July 15th
- 05/16/22
- Tilray call volume above normal and directionally bullish
- 06/16/22
- UiPath put volume heavy and directionally bearish
- 06/13/22
- UiPath put volume heavy and directionally bearish
- 06/08/22
- UiPath call volume above normal and directionally bullish
- 06/01/22
- UiPath options imply 12.2% move in share price post-earnings
- 08/08/22
- Nokia call volume above normal and directionally bullish
- 07/26/22
- Nokia call volume above normal and directionally bullish
- 07/25/22
- Nokia call volume above normal and directionally bullish
- 07/25/22
- Unusually active option classes on open July 25th
NCLH Norwegian Cruise Line - 07/18/22
- Early notable gainers among liquid option names on July 18th
- 07/07/22
- Unusually active option classes on open July 7th
- 06/30/22
- Unusually active option classes on open June 30th
- 06/27/22
- Unusually active option classes on open June 27th
- 07/21/22
- Micron put volume heavy and directionally bearish
- 07/01/22
- Notable open interest changes for July 1st
- 06/30/22
- Micron options imply 5.0% move in share price post-earnings
- 06/03/22
- Unusually active option classes on open June 3rd
- 04/20/22
- Lam Research options imply 4.5% move in share price post-earnings
- 03/29/22
- Unusually active option classes on open March 29th
- 08/08/22
- Unusually active option classes on open August 8th
- 08/02/22
- Largest borrow rate increases among liquid names
- 05/25/22
- Unusually active option classes on open May 25th
- 08/08/22
- Enovix put volume heavy and directionally bearish
- 08/05/22
- Enovix put volume heavy and directionally bearish
- 07/29/22
- Enovix call volume above normal and directionally bullish
- 05/11/22
- Enovix options imply 13.5% move in share price post-earnings
- 08/09/22
- Notable open interest changes for August 9th
- 08/05/22
- Bed Bath & Beyond call volume above normal and directionally bullish
- 08/05/22
- Unusually active option classes on open August 5th
- 05/26/22
- Unusually active option classes on open May 26th
|